Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities.

Cergutuzumab amunaleukin comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent CEA-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding.
The activation of NK cells by Cergutuzumab amunaleukin (CEA-IL2v; 0.001-1000 nM) translated into increased killing of the CEA-positive colon cancer cell line LS180 accompanied by increased release of Granzyme B, IFNγ and RANTES and upregulation of CD25 and CD69 on NK cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

In tumor-free mice, a strong expansion of peripheral CD⁸⁺ T and NK cells after treatment with 0.5 and 2 mg/kg Cergutuzumab amunaleukin (CEA-IL2v; i.v.; once) is observed.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

In tumor-free mice, a strong expansion of peripheral CD⁸⁺ T and NK cells after treatment with 0.5 and 2 mg/kg Cergutuzumab amunaleukin (CEA-IL2v; i.v.; once) is observed.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Christian Klein, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017 Jan 11;6(3):e1277306.  [Content Brief]